Affordable Access

Publisher Website

Cost–utility analysis of vaccination against HPV in Israel

Authors
Journal
Vaccine
0264-410X
Publisher
Elsevier
Publication Date
Volume
25
Identifiers
DOI: 10.1016/j.vaccine.2007.07.018
Keywords
  • Cervical Cancer
  • Vaccination
  • Cost–Utility Analysis

Abstract

Abstract Using WHO-CHOICE methodology, we calculated cost–utility ratios for various interventions (PAP smear, HPV-DNA testing, VIA and vaccination against HPV) at various frequencies to reduce the burden of cervical cancer and condyloma (in the case of the HPV vaccination) in Israel, which has a low prevalence of cervical cancer. Assuming non-waning efficacy, HPV vaccinations will become cost-effective, very cost-effective and cost saving when the cost per dose falls below $96.85, $50.42 and $27.20, respectively. Attempts should be made to raise compliancy with PAP smears from the current opportunistic 12.2–20.0% per annum either before and/or after the vaccination is introduced.

There are no comments yet on this publication. Be the first to share your thoughts.